Dante Labs appoints Mark Van Oene to board of directors

Van Oene said: “I’m excited to be joining Dante’s board in order to help scale the business as the need for genomics in healthcare is realised

Dante Labs, a genomics and precision medicine company, has announced the appointment of Mark Van Oene as a member of its board of directors. Van Oene is the COO at Pacific Biosciences, a provider of sequencing solutions.

“I’m so pleased to welcome Mark Van Oene to the Dante Labs board,” said Dante Labs CEO Andrea Riposati. “We are confident we will greatly benefit from Mark’s proven leadership in scaling Dante’s global commercial organisation to serve more people with the genomic information needed to treat and prevent disease.”

Van Oene said: “I’m excited to be joining Dante’s board in order to help scale the business as the need for genomics in healthcare is realised and plays a more essential role in drug development and precision medicine.”

Van Oene has deep expertise and leadership in the field of genomics, driving strategic planning and corporate development activities and managing research, development and manufacturing in his role at Pacific Biosciences. Prior to that, he held several key leadership roles at Illumina, ultimately serving as CCO with his appointment in 2017. Prior to Illumina, he was the Director of Genotyping Services in Ellipsis Biotherapeutics. Van Oene will join Illumina COO Bob Ragusa and GRAIL SVP Mark Morgan to the Dante Labs board of directors.

Companies